A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Ocular HypertensionOpen-Angle Glaucoma
Interventions
DRUG

Latanoprost Punctal Plug Delivery System (L-PPDS)

Latanoprost Punctal Plug Delivery System (L-PPDS)

Trial Locations (18)

11563

Ophthalmic Consultants of Long Island, Lynbrook

12159

Dr. Steven T. Simmons, Slingerlands

19107

Wills Eye Hospital, Phildelphia

19148

Philadelphia Eye Associates, Philadelphia

33901

Eye Associates of Fort Myers, Fort Myers

33904

Argus Research at Cape Coral Eye Center, Cape Coral

37803

University Eye Surgeons, Maryville

38119

Total Eye Care, Memphis

41017

Cincinnati Eye Institute, Edgewood

46202

Indiana Universtiy - Eugene and Marilyn Glick Eye Institute Ophthalmology Center, Indianapolis

49085

Great Lakes Eye Care, Saint Joseph

55420

Chu Vision Institute, Bloomington

63090

Comprehensive Eye Care, Ltd., Washington

63131

Ophthalmology Associates, St Louis

85050

Arizona Glaucoma Specialists, Phoenix

85225

Arizona Eye Center, Chandler

89148

Abrams Eye Institute, Las Vegas

90505

Wolstan & Goldberg Eye Associates, Torrance

Sponsors
All Listed Sponsors
lead

Mati Therapeutics Inc.

INDUSTRY

NCT02014142 - A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma | Biotech Hunter | Biotech Hunter